Naoufal Hjira , Adil Boudhas , Rachid Frikh , Noureddine Baba , Mohammed Oukabli , Mohammed Boui
{"title":"口服特比萘芬与Von Zumbusch脓疱性银屑病有关","authors":"Naoufal Hjira , Adil Boudhas , Rachid Frikh , Noureddine Baba , Mohammed Oukabli , Mohammed Boui","doi":"10.1016/j.jdds.2017.06.002","DOIUrl":null,"url":null,"abstract":"<div><p>Adverse skin reactions have been reported in 2.7% of patients receiving oral terbinafine. Less common but life-threatening reactions include acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, toxic epidermal necrolysis, exacerbation or induction of psoriasis.</p><p>We report a case of a 28<!--> <!-->year-old woman with no history of psoriasis, the patient presented generalized pustular eruption, erythroderma, prolonged fever and altered general conditions, associated with initiation of oral terbinafine. The histological analysis of the cutaneous biopsy was compatible with pustular psoriasis. The intake of terbinafine was discontinued and treatment by acitretin 25<!--> <!-->mg/day associated with emollient cream was started. The evolution was marked by resolution of skin eruption and disappearance of the fever in a few days. The complete remission was reached 2<!--> <!-->months later.</p><p>The diagnosis of severe generalized pustular psoriasis (GPP), type Von Zumbusch associated with initiation of oral terbinafine was made.</p><p>The present case indicates that terbinafine is a drug that may be associated with the development of psoriasis de novo or its exacerbation.</p></div>","PeriodicalId":43409,"journal":{"name":"Journal of Dermatology & Dermatologic Surgery-JDDS","volume":"21 2","pages":"Pages 91-94"},"PeriodicalIF":0.2000,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jdds.2017.06.002","citationCount":"3","resultStr":"{\"title\":\"Von Zumbusch’s pustular psoriasis associated with oral terbinafine\",\"authors\":\"Naoufal Hjira , Adil Boudhas , Rachid Frikh , Noureddine Baba , Mohammed Oukabli , Mohammed Boui\",\"doi\":\"10.1016/j.jdds.2017.06.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Adverse skin reactions have been reported in 2.7% of patients receiving oral terbinafine. Less common but life-threatening reactions include acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, toxic epidermal necrolysis, exacerbation or induction of psoriasis.</p><p>We report a case of a 28<!--> <!-->year-old woman with no history of psoriasis, the patient presented generalized pustular eruption, erythroderma, prolonged fever and altered general conditions, associated with initiation of oral terbinafine. The histological analysis of the cutaneous biopsy was compatible with pustular psoriasis. The intake of terbinafine was discontinued and treatment by acitretin 25<!--> <!-->mg/day associated with emollient cream was started. The evolution was marked by resolution of skin eruption and disappearance of the fever in a few days. The complete remission was reached 2<!--> <!-->months later.</p><p>The diagnosis of severe generalized pustular psoriasis (GPP), type Von Zumbusch associated with initiation of oral terbinafine was made.</p><p>The present case indicates that terbinafine is a drug that may be associated with the development of psoriasis de novo or its exacerbation.</p></div>\",\"PeriodicalId\":43409,\"journal\":{\"name\":\"Journal of Dermatology & Dermatologic Surgery-JDDS\",\"volume\":\"21 2\",\"pages\":\"Pages 91-94\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2017-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.jdds.2017.06.002\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Dermatology & Dermatologic Surgery-JDDS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S235224101730021X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatology & Dermatologic Surgery-JDDS","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S235224101730021X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 3
摘要
据报道,接受口服特比萘芬治疗的患者中有2.7%出现皮肤不良反应。不太常见但危及生命的反应包括急性全身性脓疱病(AGEP)、史蒂文斯-约翰逊综合征、中毒性表皮坏死松解、银屑病加重或诱发。我们报告一例28岁的女性,无牛皮癣病史,患者表现为全身脓疱疹,红皮病,持续发烧和一般情况改变,与口服特比萘芬的开始有关。皮肤活检的组织学分析符合脓疱性牛皮癣。停用特比萘芬,开始用阿维素25mg /天联合润肤霜治疗。这种演变的特点是皮肤出疹的消退和几天内发烧的消失。2个月后完全缓解。诊断为严重广泛性脓疱性银屑病(GPP), Von Zumbusch型与口服特比萘芬开始相关。本病例表明特比萘芬是一种可能与牛皮癣新发或其恶化有关的药物。
Von Zumbusch’s pustular psoriasis associated with oral terbinafine
Adverse skin reactions have been reported in 2.7% of patients receiving oral terbinafine. Less common but life-threatening reactions include acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, toxic epidermal necrolysis, exacerbation or induction of psoriasis.
We report a case of a 28 year-old woman with no history of psoriasis, the patient presented generalized pustular eruption, erythroderma, prolonged fever and altered general conditions, associated with initiation of oral terbinafine. The histological analysis of the cutaneous biopsy was compatible with pustular psoriasis. The intake of terbinafine was discontinued and treatment by acitretin 25 mg/day associated with emollient cream was started. The evolution was marked by resolution of skin eruption and disappearance of the fever in a few days. The complete remission was reached 2 months later.
The diagnosis of severe generalized pustular psoriasis (GPP), type Von Zumbusch associated with initiation of oral terbinafine was made.
The present case indicates that terbinafine is a drug that may be associated with the development of psoriasis de novo or its exacerbation.